These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 23340734)

  • 1. Mutations in ERBB4 may have a minor role in melanoma pathogenesis.
    Manca A; Lissia A; Cossu A; Rubino C; Ascierto PA; Stanganelli I; Palmieri G
    J Invest Dermatol; 2013 Jun; 133(6):1685-7. PubMed ID: 23340734
    [No Abstract]   [Full Text] [Related]  

  • 2. A therapeutic opportunity in melanoma: ErbB4 makes a mark on skin.
    Settleman J
    Cancer Cell; 2009 Oct; 16(4):278-9. PubMed ID: 19800573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutated ERBB4: a novel drug target in metastatic melanoma?
    Kurppa K; Elenius K
    Pigment Cell Melanoma Res; 2009 Dec; 22(6):708-10. PubMed ID: 19735458
    [No Abstract]   [Full Text] [Related]  

  • 4. No evidence for ErbB4 gene amplification in malignant melanoma.
    Brockhoff G; Bock M; Gantner S; Hafner C
    Acta Derm Venereol; 2011 Jun; 91(4):488-90. PubMed ID: 21547347
    [No Abstract]   [Full Text] [Related]  

  • 5. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.
    Prickett TD; Agrawal NS; Wei X; Yates KE; Lin JC; Wunderlich JR; Cronin JC; Cruz P; Rosenberg SA; Samuels Y
    Nat Genet; 2009 Oct; 41(10):1127-32. PubMed ID: 19718025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR in melanoma: clinical significance and potential therapeutic target.
    Boone B; Jacobs K; Ferdinande L; Taildeman J; Lambert J; Peeters M; Bracke M; Pauwels P; Brochez L
    J Cutan Pathol; 2011 Jun; 38(6):492-502. PubMed ID: 21352258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical markers and driving mechanisms in melanoma progression: VEGF-C, RhoC, c-Ski/SnoN and EGFR.
    Boone B; Brochez L
    Verh K Acad Geneeskd Belg; 2009; 71(5):251-94. PubMed ID: 20232784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The absence of the ERBB4 hotspot mutations in melanomas in patients from southern China.
    Zhou QM; Li W; Guan YX; Zhang X; Chen XC; Ding Y; Wen XZ; Peng RQ; Yan SM; Zhang XS
    Chin J Cancer; 2013 Jul; 32(7):410-4. PubMed ID: 23237222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No evidence for c-erbB-2 overexpression in cutaneous melanoma.
    Fink-Puches R; Pilarski P; Schmidbauer U; Kerl H; Soyer HP
    Anticancer Res; 2001; 21(4A):2793-5. PubMed ID: 11724356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between the germline MC1R variants and somatic BRAF/NRAS mutations in melanoma tumors.
    Scherer D; Rachakonda PS; Angelini S; Mehnert F; Sucker A; Egberts F; Hauschild A; Hemminki K; Schadendorf D; Kumar R
    J Invest Dermatol; 2010 Dec; 130(12):2844-8. PubMed ID: 20720566
    [No Abstract]   [Full Text] [Related]  

  • 11. BRAF point mutations in primary melanoma show different prevalences by subtype.
    Sasaki Y; Niu C; Makino R; Kudo C; Sun C; Watanabe H; Matsunaga J; Takahashi K; Tagami H; Aiba S; Horii A
    J Invest Dermatol; 2004 Jul; 123(1):177-83. PubMed ID: 15191558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re: Determinants of BRAF mutations in primary melanomas.
    Purdue MP
    J Natl Cancer Inst; 2005 Mar; 97(5):401-2; author reply 402. PubMed ID: 15741578
    [No Abstract]   [Full Text] [Related]  

  • 13. Progression of NRAS and BRAF mutations in cutaneous melanoma.
    Rosso R; Romagosa Y; Kirsner RS
    J Invest Dermatol; 2009 Jun; 129(6):1318. PubMed ID: 19434085
    [No Abstract]   [Full Text] [Related]  

  • 14. A germline oncogenic MITF mutation and tumor susceptibility.
    Paillerets BB; Lesueur F; Bertolotto C
    Eur J Cell Biol; 2014; 93(1-2):71-5. PubMed ID: 24290354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scalp melanoma in a woman with LEOPARD syndrome: possible implication of PTPN11 signaling in melanoma pathogenesis.
    Cheng YP; Chiu HY; Hsiao TL; Hsiao CH; Lin CC; Liao YH
    J Am Acad Dermatol; 2013 Oct; 69(4):e186-7. PubMed ID: 24034393
    [No Abstract]   [Full Text] [Related]  

  • 16. MITF pathway mutations in melanoma.
    Yokoyama S; Salma N; Fisher DE
    Pigment Cell Melanoma Res; 2009 Aug; 22(4):376-7. PubMed ID: 19558635
    [No Abstract]   [Full Text] [Related]  

  • 17. Transcriptome sequencing of melanocytic nevi and melanomas from Grm1 transgenic mice to determine melanoma driver mutations.
    de Jel MM; Engelmann JC; Kunz M; Schiffner S; Kuphal S; Bosserhoff AK
    Pigment Cell Melanoma Res; 2014 Jul; 27(4):678-80. PubMed ID: 24661573
    [No Abstract]   [Full Text] [Related]  

  • 18. DNA damage and repair in melanoma and non-melanoma skin cancer.
    Camplejohn RS
    Cancer Surv; 1996; 26():193-206. PubMed ID: 8783574
    [No Abstract]   [Full Text] [Related]  

  • 19. Detection of B-RAF and N-RAS mutations in human melanoma.
    Goydos JS; Mann B; Kim HJ; Gabriel EM; Alsina J; Germino FJ; Shih W; Gorski DH
    J Am Coll Surg; 2005 Mar; 200(3):362-70. PubMed ID: 15737846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Superficial spreading melanoma].
    Debarbieux S; Thomas L;
    Ann Dermatol Venereol; 2015 Jan; 142(1):66-9. PubMed ID: 25600798
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.